rs104894805 — EMD Pro183His (P183H)

Pathogenic missense variant in emerin that weakens nuclear lamina interactions, causing X-linked Emery-Dreifuss muscular dystrophy with progressive cardiac conduction defects and cardiomyopathy

See your personal result for EMD

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Emerin Pro183His Variant — EDMD's Hidden Cardiac Risk

Emerin is a protein that anchors to the inner nuclear membrane of muscle cells, acting as a structural scaffold that links chromatin to the nuclear lamina and cytoskeleton11 cytoskeleton
The nuclear lamina is a protein meshwork just inside the nuclear membrane; emerin's interactions with lamin A/C, lamin B, and nuclear actin help the nucleus resist mechanical stress during muscle contractions. When emerin is absent or dysfunctional, repeated mechanical stress during muscle contraction causes nuclear envelope instability, DNA damage, and progressive muscle and cardiac cell death. The result is Emery-Dreifuss muscular dystrophy (EDMD)22 Emery-Dreifuss muscular dystrophy (EDMD)
A rare inherited disease characterized by three defining features: early joint contractures, slow-progressive muscle wasting, and life-threatening cardiac conduction defects. First fully described by Alan Emery and Fritz Dreifuss in the 1960s — one of the few muscular dystrophies where sudden cardiac death, not muscle weakness, is the leading cause of death.

The Pro183His variant (c.548C>A, ClinVar VCV000011178) replaces a structurally critical proline at position 183 with histidine. Unlike null mutations that eliminate emerin entirely, Pro183His produces a stable protein of normal size that reaches the nuclear membrane — but with weakened binding to its interaction partners33 weakened binding to its interaction partners
Proline at position 183 is essential for emerin's three-dimensional conformation; substituting histidine disrupts local protein folding without eliminating the protein, producing a partial loss-of-function phenotype.

The Mechanism

[Biochemical studies | Ellis et al., Human Genetics, 1999 — PMID 10323252] showed that Pro183His emerin migrates identically to wild-type on gel electrophoresis and is expressed at normal levels, but its interactions with nuclear lamina components are measurably weakened. A subsequent structural study (Herrada et al., ACS Chemical Biology, 2015 — PMID 2641500144 Herrada et al., ACS Chemical Biology, 2015 — PMID 26415001) found that Pro183His also promotes abnormal emerin self-oligomerization and partial mislocalization away from the inner nuclear membrane. The net result is a nucleus that is structurally compromised under the repetitive mechanical loading of cardiac and skeletal muscle contraction — less severe than a complete emerin knockout, but sufficient to cause progressive cell death over years to decades.

Cardiac involvement in EDMD reflects emerin's additional role at cardiac desmosomes and intercalated discs55 cardiac desmosomes and intercalated discs
Specialized junctions between heart muscle cells that transmit force and electrical signals; emerin localizes here in addition to the nuclear envelope, potentially disrupting both structural integrity and electrical conduction. This dual localization explains why the cardiac phenotype — conduction defects, atrial arrhythmias, and progressive cardiomyopathy — can occur even before overt muscle weakness becomes apparent.

The Evidence

Cardiac risk in males: A 2023 European Heart Journal study (Cannie et al., Eur Heart J, 2023 — PMID 3763947366 Cannie et al., Eur Heart J, 2023 — PMID 37639473) followed 38 males with pathogenic EMD variants over a median of 65 months. Nine (23.7%) developed malignant ventricular arrhythmia (MVA), with an incidence rate of 4.8 per 100 person-years — statistically comparable to the 6.6 per 100 person-years seen in the more widely studied LMNA-related EDMD. Five (13.2%) developed end-stage heart failure. Median age at cardiac diagnosis in affected males was 30.5 years. The authors concluded that early ICD implantation should be considered in male EMD variant carriers with cardiac disease.

Carrier females: Female carriers were historically considered low-risk, but the same 2023 cohort found that 42.9% of female carriers developed cardiac complications — at a much later median age of 58.6 years. No female carrier in the study developed malignant ventricular arrhythmia or end-stage heart failure, but the high proportion with late-onset cardiac disease (conduction defects, atrial arrhythmias) establishes that female carriers require ongoing cardiac surveillance well into later life.

Phenotype of Pro183 missense vs. null mutations: Yates et al., Neuromuscular Disorders, 1999 — PMID 1038290977 Yates et al., Neuromuscular Disorders, 1999 — PMID 10382909 found that patients with Pro183 missense mutations have a later age of onset for skeletal muscle symptoms compared to patients with null mutations, consistent with partial rather than complete emerin loss-of-function. Importantly, the age of onset for cardiac involvement was not significantly different from null mutation carriers, emphasizing that cardiac risk cannot be inferred from skeletal muscle severity.

Practical Actions

The cardinal rule for EDMD is that cardiac disease causes the most serious morbidity and mortality, and it can be silent until a life-threatening event occurs. Annual cardiac screening — ECG, 24-hour Holter monitoring, and echocardiography — is essential for affected males beginning at diagnosis and for carrier females beginning in middle age. The 2023 data showing MVA rates comparable to LMNA-related EDMD strongly supports ICD consideration for male variant carriers who develop cardiac abnormalities. Refer to a cardiomyopathy or inherited cardiac disease specialist.

Genetic counseling for the extended family is equally important: in X-linked EDMD, an affected male passes the variant to all daughters (who become carriers) and no sons. A carrier female has a 50% chance of passing the variant to each son (who would be affected) and a 50% chance of passing it to each daughter (who would become a carrier).

Interactions

EMD-related EDMD follows X-linked inheritance, which means phenotype depends critically on biological sex and X-inactivation status in female carriers. In females, random X-inactivation determines what proportion of cells express the normal vs variant emerin allele. Carrier females with skewed X-inactivation — where the variant-bearing X is disproportionately active — may show earlier or more severe cardiac manifestations. There is no documented gene-gene interaction between EMD and other cardiac laminopathy genes (e.g., LMNA) that changes clinical management, since both encode nuclear envelope structural proteins and the clinical concern (cardiac monitoring and ICD consideration) is the same.

Genotype Interpretations

What each possible genotype means for this variant.

CC Unaffected / Non-carrier Normal

No Pro183His variant — standard emerin function

You carry the common reference allele at this position. In males, this means normal emerin expression and no elevated risk for Emery-Dreifuss muscular dystrophy from this variant. In females, CC indicates you are not a carrier of this specific pathogenic EMD variant. The vast majority of people share this result. Note that other pathogenic EMD variants may be present in your family if EDMD has been diagnosed through other testing.

AA Affected (Hemizygous Male / Homozygous Female) High Risk

Carries the Pro183His variant — high risk of cardiac conduction disease and cardiomyopathy

The Pro183His variant produces emerin protein that reaches the nuclear membrane at near-normal levels but with significantly weakened interactions with lamin A/C, lamin B, and nuclear actin. Structural studies confirm that P183H also promotes abnormal emerin oligomerization and partial mislocalization. Under the repetitive mechanical demands of muscle contraction, this structural compromise leads to progressive loss of cardiomyocytes and conduction system cells.

The clinical trajectory in affected males typically unfolds over decades: joint contractures (elbows, Achilles tendons, posterior neck) appear in childhood; humeroperoneal muscle weakness develops in the teens and twenties; cardiac conduction disease (bradycardia, AV block, atrial arrhythmias) appears by the second to third decade; ventricular arrhythmias and cardiomyopathy follow. Sudden cardiac death can occur before the cardiac diagnosis is made, making systematic surveillance essential from the time of genetic diagnosis.

Pro183His missense typically produces a milder skeletal muscle phenotype than null alleles (later onset of contractures and weakness), but cardiac disease onset timing is similar to null mutations. Do not use milder muscle symptoms as evidence of lower cardiac risk.

For affected males who develop cardiac dysfunction: the 2023 Cannie et al. study (N=38 males, median follow-up 65 months) found incidence of malignant ventricular arrhythmia at 4.8 per 100 person-years, comparable to LMNA- related EDMD. ICD implantation should be discussed with a cardiac electrophysiologist once cardiac involvement is detected.

AC Carrier Female Carrier

Carrier of the Pro183His variant — cardiac monitoring required in later life

X-linked inheritance in EDMD means that female carriers have one functional and one Pro183His-carrying X chromosome. In most cells, random X-inactivation silences one X, so approximately 50% of your muscle and cardiac cells express normal emerin while the other 50% express Pro183His-weakened emerin. This mosaic expression generally protects against skeletal muscle disease but does not fully protect the heart, where even partial emerin dysfunction — especially at cardiac intercalated discs and desmosomes — can disrupt electrical conduction over decades.

The 2023 Cannie et al. study is the largest prospective follow-up of EMD variant carriers to date and documented a substantially higher proportion of cardiac-affected females than previously reported. No malignant ventricular arrhythmia occurred in females, but late-onset conduction disease (first- and second-degree AV block, atrial fibrillation) is frequent enough to warrant structured surveillance.